Pfizer buys cancer drug maker Medivation for $14 billion
Pfizer announced a $14 billion deal for Medivation, a biotech company that makes an important cancer drug. Medivation’s portfolio includes Xtandi, a drug that treats prostate cancer. Pfizer said Xtandi generated approximately $2.2 billion in worldwide sales, and the purchase should add to its earnings per share immediately. Pfizer will pay $81.50 in cash for […]